Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers

Transgene, Jennerex Cancer Therapy Improves Survival in Study

Transgene SA and Jennerex Biotherapeutics said the high doses of their JX594/TG6006 therapy improved overall survival in advanced liver cancer patients, citing a mid-stage study of 30 patients.

Patients receiving the treatment at the higher dose lived a medial of 13.8 months, compared with 6.7 months for those who received the lower dose, Strasbourg, France-based Transgene and San Francisco-based Jennerex said in an e-mailed statement today. The findings are being presented at the American Association for the Study of Liver Diseases meeting in San Francisco today.

JX594/TG6006 is a virus that is engineered to target and destroy cancerous cells, according to the companies.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.